(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 49.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.09%.
Kura Oncology's revenue in 2026 is $77,225,000.On average, 18 Wall Street analysts forecast KURA's revenue for 2026 to be $8,416,475,203, with the lowest KURA revenue forecast at $7,033,760,302, and the highest KURA revenue forecast at $9,805,239,426. On average, 17 Wall Street analysts forecast KURA's revenue for 2027 to be $17,141,821,675, with the lowest KURA revenue forecast at $12,140,455,675, and the highest KURA revenue forecast at $26,573,426,501.
In 2028, KURA is forecast to generate $22,355,803,555 in revenue, with the lowest revenue forecast at $14,410,730,672 and the highest revenue forecast at $39,776,071,967.